Stayble Therapeutics AB (STU:4K4) EV-to-EBIT : 0.61 (As of May. 14, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Stayble Therapeutics AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Stayble Therapeutics AB's Enterprise Value is €-1.17 Mil. Stayble Therapeutics AB's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was €-1.92 Mil. Therefore, Stayble Therapeutics AB's EV-to-EBIT for today is 0.61.

The historical rank and industry rank for Stayble Therapeutics AB's EV-to-EBIT or its related term are showing as below:

STU:4K4' s EV-to-EBIT Range Over the Past 10 Years
Min: -7.03 Med: 0 Max: 1.54
Current: 0.62

During the past 7 years, the highest EV-to-EBIT of Stayble Therapeutics AB was 1.54. The lowest was -7.03. And the median was 0.00.

STU:4K4's EV-to-EBIT is ranked better than
73.04% of 434 companies
in the Biotechnology industry
Industry Median: 9.44 vs STU:4K4: 0.62

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Stayble Therapeutics AB's Enterprise Value for the quarter that ended in Sep. 2023 was €11.49 Mil. Stayble Therapeutics AB's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was €-1.92 Mil. Stayble Therapeutics AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -16.74%.

Stayble Therapeutics AB EV-to-EBIT Historical Data

The historical data trend for Stayble Therapeutics AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stayble Therapeutics AB EV-to-EBIT Chart

Stayble Therapeutics AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EV-to-EBIT

Get a 7-Day Free Trial

-3.80

-4.16

-1.74

Stayble Therapeutics AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EV-to-EBIT	Get a 7-Day Free Trial															-1.76	-1.74	-0.91	-1.22	-6.06

Competitive Comparison of Stayble Therapeutics AB's EV-to-EBIT

For the Biotechnology subindustry, Stayble Therapeutics AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stayble Therapeutics AB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stayble Therapeutics AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Stayble Therapeutics AB's EV-to-EBIT falls into.

Stayble Therapeutics AB EV-to-EBIT Calculation

Stayble Therapeutics AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	-1.173	/	-1.924
	=	0.61

Stayble Therapeutics AB's current Enterprise Value is €-1.17 Mil.
Stayble Therapeutics AB's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.92 Mil.

Stayble Therapeutics AB (STU:4K4) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Stayble Therapeutics AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 )	=	EBIT	/	Enterprise Value (Q: Sep. 2023 )
	=	-1.924	/	11.4910571
	=	-16.74 %

Stayble Therapeutics AB's Enterprise Value for the quarter that ended in Sep. 2023 was €11.49 Mil.
Stayble Therapeutics AB's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.92 Mil.

Stayble Therapeutics AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Stayble Therapeutics AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Stayble Therapeutics AB (STU:4K4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (STU:4K4) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

STABL:Sweden 4K4:Germany

Address

Medicinaregatan 8a, Gothenburg, SWE, SE-413 90

Website

http://www.staybletherapeutics.com

Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.

Stayble Therapeutics AB (STU:4K4) Headlines

No Headlines